CDL Laboratories provides acccess to ClarityDX Prostate for men at risk of having aggressive prostate cancer
Quebec patients undergoing prostate cancer screening will now be able to make better informed decisions about their health following a high prostate-specific antigen (PSA) level.
ClarityDX Prostate combines biological and clinical information using AI-powered learning to generate a risk score for aggressive prostate cancer. The score will aid healthcare providers and their patients to make more informed decisions following a high PSA test.
This advancement in men’s health will empower our 3,500 healthcare professionals and will provide reassurance to tens of thousands of patients every year.
What is ClarityDX Prostate?
ClarityDX Prostate is a blood test developed by Nanostics that combines the lab results of two biomarkers (total PSA and free PSA) and up to five clinical features (age, previous negative prostate biopsy status, digital rectal exam findings, prostate volume, and PI-RADS).
A score is generated to predict the risk of clinically significant prostate cancer, defined as a Gleason grade 2 group or higher on prostate biopsy. The results will aid patients in the decision to proceed to a an mpMRI and/or a biopsy.
About CDL Laboratories
Established in 1993, CDL Laboratories is a leading provider of diagnostic laboratory services in Quebec. At the forefront of the medical testing industry, its mission is fueled by a commitment to integrating the most advanced diagnostic equipment and state-of-the-art technologies to deliver precise results in industry-leading turn-around times. An innovator in the Canadian healthcare landscape, CDL Laboratories bolsters an unwavering dedication to the highest quality and excellence with over 1.4M tests per year. It is the most accredited laboratory in the province and a Roche Diagnostics showcase for over 25 years. CDL Laboratories is a subsidiary of the ELNA Medical Group, Canada’s largest integrated network of medical clinics and diagnostic services.
